MIRA Pharmaceuticals says DEA determined its three drug candidates are not controlled substances

MIRA Pharmaceuticals says the U.S. DEA confirmed after a scientific review that its three lead drug candidates, SKNY-1, Ketamir-2 and MIRA-55, are not classified as controlled substances. Ketamir-2 is moving toward Phase 2 clinical development and MIRA-55 targets an IND submission in early 2027.

Detected & updated continuously · Source: Nebula